Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...133134135136137138139140141142143...170171»
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, fondaparinux / Generic mfg., enoxaparin sodium / Generic mfg.
    Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_1968;    
    However, AA is incapable of neutralizing the anti-Xa effects of E and F. This may be due to the relatively differential affinities of enoxaparin and fondaparinux AT complex to factor Xa rendering it inhibited in the presence of AA. These studies also demonstrate that the primary surrogate marker anti-Xa activity for measuring the activities of anti-Xa agents is not proportional to the anticoagulant and thrombin generation inhibitory effects of these agents.
  • ||||||||||  enoxaparin sodium / Generic mfg.
    The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_1964;    
    Use of warfarin is associated with inferior outcomes among non-cirrhotic PVT patients when compared with other forms of AC. Patients harboring JAK2V617, and to a lesser extent those without a clear predisposing factor for PVT, have inferior outcomes compared with other non-cirrhotic PVT patients.
  • ||||||||||  enoxaparin sodium / Generic mfg.
    Incidental Pulmonary Embolism. Analysis of Mayo Clinic Venous Thromboembolism Database (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_1956;    
    Additionally, patients with iPE more often had metastatic disease which was associated with higher mortality. Recurrent VTE and bleeding outcomes were similar in patients with iPE and sPE, this was independent of the presence of underlying malignancy.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation (W314, Level 3 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_1517;    
    Treatment of children with bodyweight-adjusted rivaroxaban regimens resulted in exposures similar to those previously observed in adults receiving 20 mg once daily dosing and the level of exposure was not related to the efficacy, bleeding, or adverse events . Based on this analysis and in conjunction with the previously demonstrated similar efficacy and safety of rivaroxaban compared with standard anticoagulation, we conclude that the bodyweight-adjusted pediatric rivaroxaban regimens with either tablets or suspension are validated and provide a new alternative treatment option for VTE in children.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic mfg., Eliquis (apixaban) / BMS
    Heavy Menstrual Bleeding Under-Recognized in Menstruating Women Treated with Oral Anticoagulants (W307, Level 3 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_1345;    
    The majority (40.6%) were prescribed rivaroxaban as compared to apixaban (25.2%) or warfarin (34.2%). Most (67.1%) were receiving anticoagulation for the treatment of VTE although 20.1% were anticoagulated for ‘other’ reasons, including superficial thrombophlebitis and prophylaxis in the post-operative setting or for travel.
  • ||||||||||  aspirin / Generic Mfg.
    Journal:  Pulmonary Embolism While on Aspirin for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty. (Pubmed Central) -  Nov 4, 2019   
    Although the goal is to provide optimal patient care, lack of guideline consensus may lead to different postoperative recommendations. It is important for clinicians to discuss with their patients the pharmacologic options available for VTE prophylaxis, how organizations differ in their recommendations, and the limitations of these pharmacologic agents.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Retrospective data, Review, Journal:  Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. (Pubmed Central) -  Oct 31, 2019   
    Single prophylaxis strategies are more effective in prevention of deep vein thrombosis in the elective total knee replacement population than combination strategies, with rivaroxaban being the most effective. The results of the pulmonary embolism and major bleeding meta-analyses are uncertain and no clear conclusion can be made other than what is biologically plausible (eg, that no prophylaxis and mechanical prophylaxis strategies should have the lowest risk of major bleeding).
  • ||||||||||  Brilinta (ticagrelor) / AstraZeneca, Effient (prasugrel) / Eli Lilly, Daiichi Sankyo
    Clinical, Review, Journal, Combination therapy:  Ticagrelor or prasugrel vs. clopidogrel in combination with anticoagulation for treatment of acute coronary syndrome in patients with atrial fibrillation. (Pubmed Central) -  Oct 30, 2019   
    Ticagrelor and prasugrel are known to have a stronger antiplatelet effect compared to clopidogrel, however randomized studies have not been adequately powered to date allowing comparisons between ticagrelor, prasugrel and clopidogrel together in the setting of anticoagulation for the treatment of patients with ACS and AF. Careful consideration should be given to this scenario to avoid falling into the concept of sacrificing efficacy for safety.
  • ||||||||||  Review, Journal:  Current status of oral anticoagulant reversal strategies: a review. (Pubmed Central) -  Oct 30, 2019   
    Utilization of direct oral anticoagulants (DOAC) have steadily increased since their approval and are now recommended over warfarin for both stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism (VTE)...Since then, idarucizumab has been approved for dabigatran reversal and recently, andexanet alfa was granted approval for the reversal of apixaban or rivaroxaban in patients with life-threatening or uncontrolled bleeding events...Data exists describing both prothrombin complex concentrates (PCC) and andexanet alfa for DOAC reversal, however, without head-to-head comparison. Until future studies are available, current literature must be critically evaluated to aid in the clinical decision-making process of how to treat patients with life-threatening DOAC-related bleeding.
  • ||||||||||  aspirin / Generic Mfg., fondaparinux / Generic Mfg.
    Journal:  Aspirin for thromboprophylaxis in major orthopedic surgery: old drug, new tricks? (Pubmed Central) -  Oct 29, 2019   
    Recent evidence seems to support the use of aspirin in selected situations and in selected protocols. Therefore, we believe that consideration should be made about increasing the use of this old but still effective drug for perioperative prophylaxis of VTE, especially in patients for whom the administration of DOACs may be challenging.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg., Eliquis (apixaban) / BMS
    Journal:  Update on Extended Treatment for Venous Thromboembolism. (Pubmed Central) -  Oct 29, 2019   
    Many therapeutic options are now available for these patients, including antiplatelet therapy with aspirin or direct oral anticoagulants. Moreover, apixaban and rivaroxaban at prophylactic doses have demonstrated efficacy in preventing recurrences with a low risk of bleeding.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time. (Pubmed Central) -  Oct 29, 2019   
    Overall, a 1.5-1.9 × delay in PT and R values of TEG 3 hours after rivaroxaban administration is required to achieve therapeutic anti-Xa concentrations of rivaroxaban in canine plasma. The R values of TEG, specifically using tissue factors (RapidTEG, TF100, TF3700) and point-of-care PT for rivaroxaban can be used practically for therapeutic monitoring of rivaroxaban in dogs.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
    Journal:  Apixaban or rivaroxaban in the treatment of acute venous thromboembolism? (Pubmed Central) -  Oct 29, 2019   
    The R values of TEG, specifically using tissue factors (RapidTEG, TF100, TF3700) and point-of-care PT for rivaroxaban can be used practically for therapeutic monitoring of rivaroxaban in dogs. No abstract available
  • ||||||||||  Ernest Beutler Lecture and Prize (Hall D, Level 2 (Orange County Convention Center)) -  Oct 27, 2019 - Abstract #ASH2019ASH_845;    
    For years, the mainstays of anticoagulation therapy were heparin and warfarin, which target multiple reactions in the coagulation cascade to suppress thrombin generation...The newer direct oral anticoagulants (DOACs) include the thrombin inhibitor dabigatran, and the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban...Krishnaswamy will describe how incorporation of factor Xa into the prothrombinase complex modulates its specificity and efficiency to promote thrombin generation and how this information can inform novel strategies for attenuating this process.   Dr. Weitz will describe how the DOACs have transformed anticoagulation therapy and how the results of trials with factor XI inhibitors provide new insights into the pathogenesis of thrombosis and pave the way for safer therapies.